N/A N=177 Microparticles in Stored RBC as Potential Mediators of Transfusion Complications
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Transfusions and Nitric Oxide Level in Preterm Infants
Prematurity · Anemia · Necrotizing Enterocolitis
Primary: SNOHgB Levels
Phase 4 N=243 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
N/A N=1,424 Transfusion Trigger After Operations in High Cardiac Risk Patients
Myocardial Infarction · Coronary Revascularization · Acute Renal Failure
Primary: A Composite Endpoint of All-cause Post-randomization Mortality, Myocardial Infarction (MI), Coronary Revascularization, Acute Renal Failure, or Post-randomization…
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Phase 3 N=115 Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
Cardiopulmonary Bypass · Inflammation · Fibrinolysis
Primary: Allogenic Blood Product Transfusion Risk — 47.4; 56.8; 52.5; 36.8 percentage of participants — p=0.72
Phase 4 N=46 Platelet Transfusion During Neonatal Open Heart Surgery
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Phase 3 N=606 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
Hemorrhagic Fever, Ebola
Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants
Phase 3 N=87 The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
Acetabular Fractures
Primary: Allogenic Blood Transfusion Rates — 21; 13 Participants
Phase 2 N=10 Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants
Phase 2 N=102 Near Infrared Spectroscopy (NIRS) as Transfusion Indicator in Neurocritical Patients
Traumatic Brain Injury · Subarachnoid Hemorrhage · Intracerebral Hemorrhage
Primary: Number of Units of Packed Red Blood Cell Transfused — 0.9; 1.5 units — p=0.03
Phase 1 N=22 Biotin-RBC Transfusion in SCD
Sickle Cell Disease
Primary: Percentage of Biotin Labeled RBCs — 97.3; 80; 21 percentage of biotin-labeled RBCs
Phase 2 N=166 Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
Non-transfusion Dependent Thalassemia
Primary: Core Study: Change in Liver Iron Concentration (LIC) From Baseline to Week 52 — -1.95; -3.80; 0.38 mg iron (Fe)/g dry weight (dw)
Phase 3 N=479 Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II
Cigarette Smoking
Primary: Continuous Abstinence From Smoking at Ten Weeks Post-quit — 31; 21; 17; 26 participants
Phase 2 N=34 Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Myelodysplastic Syndromes
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks — 0; 6.1 Percentage of participants